82. Targeting Signal Transducer and Activator of Transcripion (STAT) 3 with Small Molecules.

Andrew E Shouksmith, Patrick T Gunning;

81. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Bettina Wingelhofer, Heidi A Neubauer, Peter Valent, Xiaonan Han, Stefan N Constantinescu, Patrick T Gunning, Mathias Müller, Richard Moriggl

Leukemia 32 (8), 1713

80. Reciprocal regulation of the Cadherin-11/Stat3 axis by caveolin-1 in mouse fibroblasts and lung carcinoma cells.
M.Geletu, R.Mohana, R.Arulanandama A.Berger-Becvar, R.Nabid, P.T.Gunning, L.Raptisa

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Volume 1865, Issue 5, May 2018, Pages 794-802

79. ProxyPhos Sensors for the Detection of Negatively Charged Membranes.
Murcar-Evans, B., Cabral, A., Toutah, K., De Araujo, E. D., Lai, A., Macdonald, P., Berger-Becvar, A., Kraskouskaya, D., Gunning P. T.,  Analyst, 2017, Accepted Manuscript DOI 10.1039/C7AN00568G

78. High-throughput thermofluor based assays for inhibitor screening of STAT SH2 domains.
De Araujo, E. D., Manaswiyoungkul, P., Israelian, J., Yuen, K., Farhangi, S., Berger, A., Abu-Jazar, L., Gunning, P. T. Pharm. Bioomed. Anal. 2017 accepted. Manuscript ID#JPBA_2017_399. IF = 3.169

77. Optimization and application studies of ProxyPhos, a chemosensor for the detection of proximally phosphorylated peptides and proteins in aqueous solutions.

Kraskouskaya, D., Cabral, A., Fong, R., Bancerz, M., Toutah, K., Rosa, D. A., Gardiner, J. E., De Araujo, E., Duodu, E., Armstrong, D., Fekl, U., Gunning, P. T. Analyst 2017, Accepted April 17th, 2017 Manuscript ID: AN-ART-11-2016-002537 IF = 4.107.

76. CD133+ brain tumour initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence.

Garg, N., Bakhshinyan, D., Venugopal, C., Rosa, D. A., Vijayakumar, T., Manoranjan, B., Hallett, R., McFarlane, N., Mahendram, S., Delaney, K., Kwiecien, J., Arpin, C. C., Lai, P-S., Gomez-Biagi, R. F., Ali, A. M., Ajani, O. A., Hassell, J., Gunning, P. T., Singh, S. K. Oncogene 2017, 5, 606-617.

75. Strategies for over-expression and purification of recombinant full length STAT5B in Escherichia coli.

De Araujo, E., Geletu, M., Gunning, P. T. Protein Expression and Purification. 2017, 129, 1-9.



74. STAT5 is a key regulator in NK cells and act as molecular switch from tumor surveillance to tumor promotion.

Maurer, B., Nivarthi, H., Wingelhofer, B., Prchal-Murphy, M., Chen, D., Winkler, S., Merkel, O., Schlederer, M., Prochazkova, J., Schiefer, A-S., Gurnhofer, E., Hofbauer, M., Thi, Thanh Pham, H., Hochgatterer, B., Bauer, E., Hoermann, G., Hoelbl-Kovacic, A., Cumaraswamy, A. A., Lewis, A. M., Eder, J., Kitzwoegerer, M., Han, X., Valent, P., Stoiber, D., Kolbe, T., Loizou, J. I., Grebien, F., Kenner, L., Gunning, P. T., Kralovics, R., Sexl, V., Mueller, M., Rülicke, T., Moriggl, R. Cancer Discovery. 2016, 4, 414-429.

73. Chronic inhibition of STAT3/STAT5 in treatment-resistant human breast cancer cell subtypes: convergence on the ROS/SUMO pathway and its effects on xCT expression and system xc- activity.

Linher-Melville, K., Nashed, M. G., Ungard, R., Gunning, P. T., Singh, G. PLoSOne. 2016, 11: e0161202.

72. Applying Small Molecule Signal Transducer and Activator of Trancription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.

Arpin, C. C., Mac, S., Cheng, H., Jiang, Y., Page, B. D. G., Kamocka, M. M., Haftchenary, S., Su, H., Ball, D., Rosa, D., Lai, P-S., Gómez-Biagi, R. F., Ali, A. M., Kerman, K., Fishel, M. L., and Gunning, P. T. Mol. Cancer Ther. 2016, 5, 794-805. IF = 6.107.

71. A Selective inhibitor of the UFM1-activating enzyme, UBA5.

da Silva, S. R., Paiva, S-L., Bancerz, M., Geletu, M., Lewis, A. M., Chen, J., Cai, Y., Lukkarila, J. L., Dhe-Paganon, S., Li, H., Gunning, P. T. BMCL 2016, 26, 4542-4547.

70. Disarming an electrophilic warhead: retaining potency in tyrosine kinase inhibitor (TKI)-resistant CML lines while circumventing pharmacokinetic liabilities.

Ali, A. M., Gómez-Biagi, R. F., Rosa, D. A., Lai, P-S. Heaton, W. L., Park, J. S., Eiring, A. M., Vellore, N. A., De Araujo, E. D., Ball, D. P., Shouksmith, A. E., Patel, A. B., Deininger, M. W., O'Hare, T., Gunning, P. T. ChemMedChem. 2016, 11, 850-861.


69. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent.

Ball, D. P., Lewis, A. M., Williams, D., Resetca, D., Wilson, D. J., Gunning, P. T. Oncotarget. 2016, 7, 20669-20679. 


68. STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion.  

Gotthardt, D., Putz, E. M., Grundschober, E., Prchal-Murphy, M., Straka, E., Kudweis, P., Heller, G., Bago-Horvath, Z., Witalisz-Siepracka, A., Cumaraswamy, A. A., Gunning, P. T., Strobl, B., Muller, M., Moriggl, R., Stockmann, C., Sexl, V. Cancer Discov. 2016, 6, 414-429. 

67. A tool for the selective sequestration of ATP and PPi to aid in-solution phosphopeptide detection assays.  

Duodu, E., Kraskouskaya, D., Gómez-Biagi, R. F., Gunning, P. T. Analyst 2016,141, 820-822. 

66. STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.  

Belton, A., Xian, L., Huso, T., Koo, M., Luo, L. Z., Turkson, J., Page, B. D. G., Gunning, P. T., Liu, G., Huso, D. L., Resar, L. M. Leukemi & Lymphoma. 2016.



65. Rationally Designed STAT3 Protein Inhibitors as Pancreatic Cancer Therapeutics.  

Arpin, C. C., Mac, S., Cheng, H., Jiang, Y., Page, B. D. G., Kamocka, M. M., Haftchenary, S., Su, H., Ball, D., Rosa, D., Lai, P-S., Gómez-Biagi, R. F., Ali, A. M., Kerman, K., Fishel, M. L., and Gunning, P. T. Mol. Cancer Ther. 2015 accepted, in press. MS# MCT-15-0003  


64. A tool for the selective sequestration of ATP and PPi to aid in-solution phosphopeptide detection assays.

Duodu, E., Kraskouskaya, D., Gunning, P. T. Analyst. 2015, in press. AN-COM-07-2015-001414. 


63. A selective inhibitor of the UFM1-activating enzyme, UBA5.  

da Silva, S. R., Paiva, S-L., Bancerz, M., Geletu, M., Lewis, A. M., Chen, J., Cai, Y., Lukkarila, J. L., Dhe-Paganon, S., Li, H., Gunning, P. T. BMCL. 2015 in press. Manuscript # MCL_BMCL-D-15-00846. DOI:10.1016/j.bmcl. 2015.10.015  


62. Targeting Signal Transducer and Activator of Transcripion (STAT) 3 with Small Molecules.  

Shouksmith, A. E., Gunning, P. T. Book chapter for Royal Society of Chemistry Book, ‘Small Molecule Transcription Factors in Oncology.’ 2015.  


61. A STAT inhibitor patent review: progress since 2011.  

Lai, P.L., Rosa, D. A., Ali, A. M., Gomez-Biagi, R. E., Ball, D. P., Shouksmith, A. E., Gunning, P. T. Ex. Opin. Ther. Pat. 2015, in press. Manuscript ID: 1086749.  


60. Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.  

Haftchenary, S, Jouk, A. O., Aubry, I., Lewis, A. M., Landry, M., Ball, D. P., Shouksmith, A. E., Collins, C. V., Tremblay, M. L., Gunning, P. T.  ACS Med. Chem. Lett. 2015, 6, 982–986.  

59. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation.  

Singh, M., Garg, N., Venugopal, C., Hallett, R., Tokar, T., McFarlane, N., Arpin, C. C., Page, B. D. G., Haftchenary, S., Todic, A., Rosa, D. A., Lai, P-S., Gómez-Biagi, R., Ali, M., Lewis, A., Geletu, M., Mahendram, S., Bakhshinyan, D., Manoranjan, B., Vora, P., Qazi, M., Murty, N. K., Hassell, J. A., Jurisica, I., Gunning, P. T., Singh, S. K. Oncotarget. 2015, 6, 27461-27477.  


58. Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells.  

Linher-Melville, K., Haftchenary, S., Gunning, P. T., Singh, G. Mol. Cell. Biochem. 2015, 405, 205-221. 

57. Developing inhibitors of STAT proteins: Targeting downstream of the kinases for treating disease.  

Lewis, A. M., Rana, R., Park, J-S., Gomez, R., Shaheen, A., Rosa, D., Gunning, P. T.  

Book chapter in “Kinomics: Approaches and Applications” by Wiley-VCH 2015, ISBN: 978-3-527-33765-1 


56. Magnetic bead-based electrochemical detection of interaction between epigallocatechin-3-gallate and STAT proteins.

Zeidan, N., Su, H., Aitken, M., Gunning, P. T., Kerman, K. Anal. Methods, 2015, 7, 3566-3569.  


55. Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.  

Arabzadeh, A., Dupaul-Chicoine, J., Breton, V., Haftchenary, S., Yumeen, S., Turbide, C., Saleh, M., McGregor, K., Greenwood, C. M. T., Akavia, U. D., Blumberg, R. S., Gunning, P. T., Beauchemin, N. Gut. 2015, in press. gutjnl-2014-308781. 


54. Selective detection of tyrosine-containing proximally phosphorylated motifs using an antenna-free Tb3+ luminescent sensor.  

Duodu, E., Kraskouskaya, D., Campbell, J., Graca-Lima, G., Gunning, P. T.  

Chem. Commun. 2015, 51, 6675 - 6677.  


53. Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia.  

Eiring, A. M., Page, B. D. G., Kraft, I. L., Zhang, T. Y., Vellore N. A., Reynolds, K. R., Senina, A., Pomicter, A. D., Khorashad, J. S., Gu, Z., Anderson, D. J., Zabriskie, M. S., Arpin, C. C., Cologouri, R., Ahmad, S., Moriggl, R., Baron, R., O’Hare, T., Gunning, P. T., Deininger, M. W. Leukemia. 2015, 29, 586-597.  




52. Changes in Signal Transducer and Activator of Transcription 3 (STAT3) Dynamics Induced by Complexation with Pharmacological Inhibitors of Src Homology 2 (SH2) Domain Dimerization.  

Resetca, D., Haftchenary, S., Gunning, P. T., Wilson, D. J. J. Biol. Chem. 2014, 289, 32538-32547.  


51. Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein.

Cumaraswamy, A.A., Lewis, A. M., Geletu, M., Todic, A., Diaz, D. B., Cheng, X. R., Brown, C. E., Laister, R. C., Muench, D., Kerman, K., Grimes, L. H., Minden, M. D., Gunning, P. T.  

ACS Med Chem Lett. 2014, 19, 1202-1206.  


50. Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells.

 Xu, G. W., Toth, J. I., daSilva, S., Paiva, S. L., Lukkarila, J. L., Hurren, R., MacLean, N., Sukhai, M. A., Bhattacharjee, R., Goard, C. A., Gunning, P. T., DhePaganon, S., Petroski, M. D.,* Schimmer, A. D.*  PLOSone. 2014, in press. e93530. doi: 10.1371.  


49. Dynamic reprogramming of signaling upon Met inhibition reveals pathways for cell proliferation and negative feedback in gastric cancer.

Lai, A. Z., Cory, S., Zhao, H., Gigoux, M., Monast, A., Guiot, M. C., Huang, S., Tofigh, A., Thompson, C., Naujokas, M., Marcus, V. A., Bertos, N., Sehat, B., Perera, R. M., Bell, E. S., Page, D. G. B., Gunning, P. T., Ferri, L.E., Hallett, M.L., Park, M. Science Signaling. 2014, 7, p. ra38.  


48. An excimer-based, turn-on fluorescent sensor for the selective detection of di-phosphorylated proteins in aqueous solution and polyacrylamide gels.

Kraskouskaya, D., Bancerz, M., Soor, H. S., Gardiner, J. E., Gunning, P. T.* J. Am. Chem. Soc. 2014, 136, 1234–1237.  


47. Electrochemical detection of the Fc-STAT3 phosphorylation and STAT3–Fc-STAT3 dimerization and inhibition.

Martic, S., Rains, M. K, Haftchenary, S., Shahani, V. M., Kraskouskaya, D., Ball, D. P., Gunning, P. T., Kraatz, H-B.*  Mol. Bio. Syst. 2014, 10, 576-580.  




46. Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.

Haftchenary, S., Luchman, H. A. Jouk, A. O., Veloso, A. J., Page, B. D. G., Cheng, X. R., Dawson, S. S., Grinshtein, N., Shahani, V. M., Kerman, K., Kaplan, D. R., Griffin, C., Aman, A. M., Al-awar, R., Weiss, S. Gunning, P. T. ACS Med. Chem. Lett. 2013, 4, 1102-1107. 


45. A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.

Shahani, V. M., Ball, D. P., Ramos, A. V., Li, Z., Spagnuolo, P. A., Haftchenary, S., Schimmer, A. D., Trudel, S., Gunning, P. T.* Bioorg. Med. Chem. 2013, 21, 5618-28. IF = 3.205. 


45. A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.

Shahani, V. M., Ball, D. P., Ramos, A. V., Li, Z., Spagnuolo, P. A., Haftchenary, S., Schimmer, A. D., Trudel, S., Gunning, P. T. Bioorg. Med. Chem. 2013, 21, 5618-28. 


44. Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma.

Page, B. D. G., Croucher, D., Li, Z. H., Haftchenary, S., Jimenez-Zepeda, V., Atkinson, J., Spagnuolo, P., Wong, Y. L., Colaguori, R., Lewis, A. M., Schimmer, A. D., Trudel, S., Gunning, P. T. J. Med.Chem. 2013, 56, 7190-7200. 


43. Identification of a potent salicylic acid-based inhibitor of tyrosine phosphatase PTP1B. 

Haftchenary, S., Ball, D. P., Aubry, I., Landry, M., Shahani, V. M., Fletcher, S., Page, B. D. G., Jouk, A. O., Tremblay, M. L., Gunning, P. T. RSC Med. Chem. Comm. 2013, 4, 987-992.  


42. Extolling the Benefits of Molecular Therapeutic Lipidation.

Avadisian, M. A., Gunning, P. T. Mol. Bio. Syst. 2013, 9, 2179-2188. 


41. Exploring a new frontier in cancer treatment: Targeting the ubiquitin and ubiquitin-like activating enzymes.

da Silva, S., Paiva, S-L., Lukkarila, J., Gunning, P. T. J. Med. Chem. 2013, 56, 2165–2177.  


40. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy.

Camporeale, A., Marino, F., Papageorgiou, A., Carai, P., Fornero, S., Fletcher, S., Page, B. D. G., Gunning, P. T., Chiarle, R., Morello, M., Jenssen, O., Levi, R., Heymans, S., Poli, V. EMBO Mol. Med. 2013, 5, 1-19. IF = 9.390. 


39. Targeting the ubiquitin E1 as a novel anti-cancer strategy.

Xu, W., daSilva, S. R., Pavia, S. L., Lukkarila, J., Schimmer, A. D., Gunning, P. T. Curr. Pharma. Design. 2013, 19, 3201-2209. 


38. Progress towards the development of SH2 domain inhibitors.

Kraskouskaya, D., Duodu, E., Arpin, C. C., Gunning, P. T. Chem. Soc. Rev., 2013, 42, 3337-3370. 


37. Exploring the structural determinants of selective phosphopeptide recognition using bivalent metal-coordination complexes.  

Kraskouskaya, D., Drewry, J. A., Duodu, E., Burger, S., Eaton, J., Cisneros, G.A., Gunning, P. T. Med. Chem. Comm. 2013, 4, 289-292. 




36. Phosphopeptide Selective Coordination Complexes as Promising Src Homology 2 Domain Mimetics.

Drewry, J. A., Duodu, E., Mazouchi, A., Spaganueulo, P., Burger, S., Gradinaru, C. C., Ayers, P., Schimmer, A. D., Gunning, P. T. Inorg. Chem, 2012, 51, 8284-8291.  


35. Progress towards direct inhibitors of Stat5 protein.

Cumaraswamy, A., Gunning, P. T. Hormone Mol. Biol. Clin. Invest. 2012, 10, 281-286.  


34. Automated Parameterization of AMBER force field terms from vibrational analysis with a focus on functionalizing a dinuclear zinc(II) scaffold.  

Burger, S., Lacasse, M., Verstraelen, T., Drewry, J. A., Gunning, P. T., Ayers, P. W. 

J. Chem. Theory and Comput. 2012, 8, 554-562. 


33. Src Homology 2 Domain Proteomimetics: Developing Phosphopeptide Selective Receptors.  

Drewry, J. A., Burger, S., Mazouchi, A. Duodu, E.,  Ayers, P., Gradinaru, C. C., Gunning, P. T. 

Chem. Commun. 2012, 3, 763-770. 


32. An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery.

Mitra, R. N., Doshi, M., Zhang, Z., Tyus, J. C., Bengtsson, N., Fletcher, S., Page, B. D. G., Turkson, J., Gesquiere, A. J., Gunning, P. T., Walter G. A., Santra, S. 

Biomaterials 2012, 33, 1500-1508. 


31. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.

Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T.,* Turkson, J. P. N. A. S. 2012, 109, 9623-9628. 


30. Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Anti-leukemia Activity.

Page, B. D. G., Khoury, H., Laister, R. C., Fletcher, S., Vellozo, M., Manzoli, A., Yue, P., Turkson, J., Minden, M. D., Gunning, P. T. J. Med. Chem. 2012, 55, 1047-1055.   


29. Inhibitors of Stat5 protein signalling.  

Cumaraswamy, A., Todic, A., Resetca, D., Minden, M. D., Gunning, P. T. 

MedChemComm, 2012, 3, 22-27. 




28. Identification of a Non-phosphorylated, Cell Permeable, Small Molecule Ligand for the Stat3 SH2 Domain. 

Page, B. D. G., Fletcher, S., Yue, P., Li, Z., Zhang, X., Sharmeen, S., Datti, A., Wrana, J. L., Trudel, S., Schimmer, A. D., Turkson, J., Gunning, P. T. Bioorg. Med.

Chem. Lett. 2011, 21, 5605-5609. 


27. Identification of NAE inhibitors exhibiting potent activity in Leukemia cells: Exploring the structural determinants of NAE Specificity. 

Lukkarila, J., da Silva, S., Ali, M., Shahani, V. M., Xu, G. W., Berman, J., Roughton, A., DhePhaganon, S., Schimmer, A. D., Gunning, P. T. ACS Med. Chem. Lett. 2011, 2, 577-582. 


26. Artificially Induced Protein–Membrane Anchorage with Cholesterol-Based Recognition Agents as a New Therapeutic Concept.

Avadisian, M., Fletcher, S., Lui, B., Zhao, W., Yue, P., Badali, D., Xu, W., Schimmer, A. D., Turkson, J., Gradinaru, C. C., Gunning, P. T. Angewandte Intl. Ed. 2011, 50, 6248-6253 


25. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. 

Fletcher, S., Page, B. D. G., Zhang, X., Yue, P., Li, Z-H., Sharmeen, S., Singh,J., Zhao, W., Schimmer, A. D., Trudel, S., Turkson, J., Gunning, P. T. ChemMedChem. 2011, 6, 1459-1470. 


24. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.

Shahani, V. M., Yue, P., Fletcher, S., Sharmeen, S., Sukhai, M. A., Luu, D. P., Zhang, X., Sun, H., Zhao, W., Schimmer, A. D., Turkson, J., Gunning, P. T. Bioorg. Med. Chem. 2011,19, 1823-1838.  


23. Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies.

Shahani, V. M., Yue, P., Haftchenary, S., Zhao, W., Lukkarila, J., Zhang, X., Ball, D., Nona, C., Gunning, P. T., Turkson, J. ACS. Med. Chem. Lett. 2011, 2, 79-84. 


22. Signal transducer and activator of transcription 3 inhibitors: a patent review.

Page, B. D. G., Ball, D. P., Gunning, P. T. Expert Opin. Ther. Patents 2011, 21, 65-83. 


21. Recent Advances in Biosensory and Medicinal Therapeutic Applications of Zinc(II) and Copper(II) Coordination Complexes. 

Drewry, J. A., Gunning, P. T. Coord. Chem. Rev., 2011, 255, 459-472. 


20. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. 

Haftchenary, S., Avadisian, M., Gunning, P. T. Anticancer Drugs 2011, 22, 115-127. 




19. Concise Access to N9-Mono, N2-Mono and N2, N9 Di-substituted Guanines via Efficient Mitsunobu Reactions. 

Fletcher, S. Shahani, V. M., Lough, A. J., Gunning, P. T. Tetrahedron 2010, 66, 4621-4632. 


18. Development of Stat3 as an accessible target for fluorescence-based inhibition assays. 

Badali, D., Lui, B., Mazouchi, A., Avadisian, M. A., Gunning, P. T., Gradinaru, C. 

JULS, 2010, 4, 18-22. 


17. A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes. 

Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., Turkson, J. 

Biochem. Pharm. 2010, 79, 1398-1409. 


16. Coordination Complex SH2 Domain Proteomimetics: An Alternative Approach to Disrupting Oncogenic Protein–Protein Interactions. 

Drewry, J. A., Fletcher, S., Peibin, Y., Marushchak, D., Zhao, W., Sumaiya, S., Zhang, X., Schimmer, A. D., Gradinaru, C., Turkson, J., Gunning, P. T. Chem. Commun. 2010, 46, 892-894. 


15. Novel asymmetrically functionalized bis-dipicolylamine metal complexes: peripheral decoration of a potent anion recognition scaffold. 

Drewry, J. A., Fletcher, S., Hassan, H., Gunning, P. T. Org. Biomol. Chem. 2009, 7, 5074–5077. 


14. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. 

Fletcher, S., Drewry, J. A., Shahani, V. M., Page, B. D. G., Gunning, P. T.  

Biochem. Cell Biol. 2009, 87, 825-833. 


13. Disruption of Transcriptionally Active Stat3 Dimers with Nonphosphorylated, Salicylic Acid-Based Small Molecules: Potent in vitro and Tumor Cell Activities. 

Fletcher, S., Singh, J., Zhang, X., Yue, P., Page, B. D. G., Sharmeen, S., Shahani, V. M., Zhao, W., Schimmer, A. D., Turkson, J., Gunning, P. T. ChemBioChem 2009, 10, 1959-1964. 


12. Single-Molecule Fluorescence Study of the Inhibition of the Oncogenic Functionality of STAT3. 

Liu, B., Badali, D., Fletcher, S., Avadisian, M., Gunning, P. T., Gradinaru, C. C. Proc. SPIE, 2009, 7386, 738605-1.  


11. A photostable, pH-invariant fluorescein derivative for single-molecule microscopy. 

Liu, B., Fletcher, S., Avadisian, M., Gunning, P. T., Gradinaru, C. C. J. Fluoresc., 2009, 19, 915-920. 


10. Facile and efficient access to 2,6,9-tri-substituted purines through sequential N9, N2 Mitsunobu reactions. 

Fletcher, S., Shahani, V., Gunning, P. T. Tet. Lett., 2009, 50, 4258-4261. 


9. Molecular approaches towards the inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein.

Fletcher, S., Turkson, J., Gunning, P. T. ChemMedChem, 2008, 3, 1159-1168. 


8. Mild, efficient and rapid O-debenzylation of electron-withdrawing, ortho-substituted phenols with trifluoroacetic acid.

Fletcher, S., Gunning, P. T. Tet. Lett. 2008, 49, 4817-4819. 


Doctoral and Postdoctoral:


7. Targeting protein-protein interactions: suppression of Stat3 dimerization via rationally designed small molecule, non-peptidic SH2 domain binders. 

Gunning, P. T., Glenn, M., Siddiquee, K. A. Z., Katt, K. P., Masson, E., Sebti, S. M., Turkson, J., Hamilton, A. D. ChemBioChem, 2008, 17, 2800-2803. 


6. Selective disruption of Stat3 dimerization by an oxazole based novel small molecule alters intracellular Stat3 processing and inhibits tumor cell survival, migration and invasion, and growth of human breast tumor xenografts.

Siddiquee, K. A. Z., Gunning, P. T., Glenn, M., Katt, W. P., Zhang, S., Schroeck, C., Sebti, S. M., Jove, R., Hamilton, A. D., Turkson, J. ACS Chem. Biol., 2007, 12, 787-798.  


5. Isoform selective inhibition of Stat1 or Stat3 homodimerization via peptidomimetic probes: structural recognition of Stat SH2 domains.

Gunning, P. T., Glenn, M., Siddiquee, K., Kim, J. S., Jove, R.,Sebti, S.M. Turkson, J., Hamilton, A. D. Bioorg. Med. Chem. Lett., 2007, 17, 1875-1878.  


4. Anion control of isomerism, crystal packing and phosphate binding in a mononuclear zinc complex. 

Fielden, J., Gunning, P. T., Long, D-L., Nutley, A., Ellern, A., Koegerler, P., Cronin, L. 

Polyhedron, 2006, 25, 3474-3480. 


3. Artificial zinc hydrolysis enzymes: synthesis of hybrid cyclophane-azamacrocyclic receptors. 

Gunning, P. T., Peacock, R. D., Benniston, A. C. J. Org. Chem., 2005, 70, 115-123. 


2. Positive ion-pair cooperativity exhibited for the binding of phosphate under physiological conditions. 

Gunning, P. T. Org. Biomol. Chem., 2005, 3, 3877-3879. 


1. Modular ditopic crown-shielded phosphate ion pair receptor.

Gunning, P. T., Peacock, R. D., Benniston, A. C. Chem. Commun., 2004, 1, 2226-2227. 























  • White LinkedIn Icon
  • White Twitter Icon